Letrozole

Letrozole is a non-steroidal, competitive aromatase inhibitor developed by Novartis and is the most potent AI in clinical use. At the standard clinical dose of 2.5 mg daily, Letrozole suppresses circulating estradiol by over 97–99% — significantly more than either Anastrozole (~85%) or Exemestane (~85–95%). It was developed for and is FDA-approved for the treatment of hormone receptor-positive breast cancer, where maximal estrogen suppression is therapeutically necessary.

Like Anastrozole, Letrozole works through competitive, reversible inhibition of the aromatase enzyme (CYP19A1). However, its binding affinity is substantially higher, which accounts for its greater potency. This is a double-edged characteristic: while maximal suppression can be advantageous in specific scenarios, it also means that standard clinical doses are vastly excessive for anabolic research applications. Researchers must dose Letrozole with far greater precision than other AIs — the margin between effective estrogen management and complete estrogen crash is narrow.

Letrozole occupies a specific niche in anabolic research: it is reserved for situations where other AIs have proven insufficient. The two most common applications are (1) emergency reversal of existing gynecomastia that has not responded to SERMs or lower-potency AIs, and (2) estrogen control on heavily aromatizing stacks where Anastrozole at standard doses fails to maintain estradiol within target range. It is not a first-line AI for routine cycle support — reaching for Letrozole when Arimidex would suffice is analogous to using a sledgehammer where a finishing nail calls for a tack hammer.

This compound is strictly for experienced researchers who are committed to regular bloodwork and precise dose titration. It is never appropriate as a first AI. Researchers who have crashed their estrogen on Letrozole report symptoms that can persist for weeks: severe joint pain, emotional blunting, sexual dysfunction, cognitive fog, and dangerously impaired lipid profiles.

Letrozole has a half-life of approximately 2 days (48 hours), supporting every-other-day or less frequent dosing. Research dosages typically range from 0.25 mg to 1.25 mg every other day — far below the clinical oncology dose. For acute gynecomastia intervention, short-term protocols of 1.25–2.5 mg daily for 7–14 days are sometimes employed, followed by a step-down to maintenance dosing. Letrozole does not carry meaningful hepatotoxicity. The primary monitoring concern is estradiol suppression — a sensitive E2 blood panel should be drawn 10–14 days after initiating or adjusting dose.